Skip to main content
Figure 2 | BMC Gastroenterology

Figure 2

From: Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

Figure 2

Individualized courses of treatment in our “real-life” cohort. Patients are grouped according to the respective guidelines [14, 15]. Each symbol represents one patient. Patients with partial response or breakthrough under BOC/TPR are not depicted in A and B, patients with partial response or breakthrough at any time are not depicted in C and D. All BOC patients and TPR patients who received a dual lead-in phase prior to BOC/TPR are included in E. [BOC = boceprevir; TPR = telaprevir; PR = pegylated interferon and ribavirin; SVR = sustained virological response; EOT = patient concluded therapy, but is short of 12 weeks after last ribavirin dose].

Back to article page